IFM Therapeutics, a biotechnology startup developing drugs that target a part of the immune system, said Wednesday Novartis exercised an option to buy its IFM Due subsidiary for $90 million upfront ...
doctors trained to the highest international standards. Through this partnership with IFM, Emagene Life will launch the Emagene Academy, a regional hub dedicated to training doctors, nutritionists, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results